ViaNautis Bio welcomes SCI Ventures as new investor, expanding CNS portfolio into spinal cord injury
- Investment supports application of ViaNautis’ polyNaut® platform to regenerative therapies for spinal cord injury, where targeted delivery remains a huge barrier
- Adds a new high-value CNS indication and provides further validation of polyNaut® as a versatile platform for precise, non-viral delivery of genetic medicines
Cambridge, UK – 9 September 2026 – ViaNautis Bio (“ViaNautis”), the biotech developing polyNaut® for precise, non‑viral delivery of genetic medicines, today announced that SCI Ventures, a specialist venture fund backed by leading clinical centres and research foundations worldwide focused on advancing treatments and cures for paralysis, has joined the company as a new investor.
